These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 28639995

  • 1. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
    Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.
    J Acquir Immune Defic Syndr; 2017 Oct 01; 76(2):177-182. PubMed ID: 28639995
    [Abstract] [Full Text] [Related]

  • 2. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM, Preexposure Prophylaxis Initiative Study Team.
    Clin Infect Dis; 2015 Aug 15; 61(4):572-80. PubMed ID: 25908682
    [Abstract] [Full Text] [Related]

  • 3. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
    Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, Smith DK, Thigpen MC, Paxton LA.
    PLoS One; 2014 Aug 15; 9(3):e90111. PubMed ID: 24625530
    [Abstract] [Full Text] [Related]

  • 4. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
    Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, Piper J, Akello CA, Kiweewa FM, Magure T, Nakabiito C, Marrazzo JM, Chirenje ZM, Riddler SA, MTN-003B Protocol Team.
    J Acquir Immune Defic Syndr; 2016 Mar 01; 71(3):287-94. PubMed ID: 26866954
    [Abstract] [Full Text] [Related]

  • 5. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.
    Clin Infect Dis; 2017 Feb 01; 64(3):317-325. PubMed ID: 28013265
    [Abstract] [Full Text] [Related]

  • 6. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K, Songtaweesin WN, Tepmongkol S, Wongharn P, Kawichai S, Suponsilchai V, Anugulruengkitt S, Puthanakit T, CE-PID - IHRI Adolescent Study Team.
    J Int AIDS Soc; 2020 Oct 01; 23(10):e25624. PubMed ID: 33040465
    [Abstract] [Full Text] [Related]

  • 7. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
    Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.
    Clin Infect Dis; 2018 Jul 18; 67(3):411-419. PubMed ID: 29415175
    [Abstract] [Full Text] [Related]

  • 8. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.
    Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, Thompson M, Grant R, Pathak S, O'Hara B, Gvetadze R, Chillag K, Grohskopf L, Buchbinder SP.
    PLoS One; 2011 Jul 18; 6(8):e23688. PubMed ID: 21897852
    [Abstract] [Full Text] [Related]

  • 9. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    JAMA Intern Med; 2015 Feb 18; 175(2):246-54. PubMed ID: 25531343
    [Abstract] [Full Text] [Related]

  • 10. Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.
    Van Slyke L, Scott M.
    J Int Assoc Provid AIDS Care; 2018 Feb 18; 17():2325958218760846. PubMed ID: 29534653
    [Abstract] [Full Text] [Related]

  • 11. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    J Acquir Immune Defic Syndr; 2016 Apr 01; 71(4):374-80. PubMed ID: 26914909
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF, Richardson R, Ebeling PR, Rojas J, Pocock N, Kerr SJ, Martinez E, Carr A, ZEST Study Investigators.
    AIDS; 2018 Sep 10; 32(14):1967-1975. PubMed ID: 29927785
    [Abstract] [Full Text] [Related]

  • 13. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.
    PLoS Med; 2018 Sep 10; 15(9):e1002655. PubMed ID: 30265679
    [Abstract] [Full Text] [Related]

  • 14. The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.
    Baranek B, Wang S, Cheung AM, Mishra S, Tan DH.
    Antivir Ther; 2020 Sep 10; 25(1):21-32. PubMed ID: 32077867
    [Abstract] [Full Text] [Related]

  • 15. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT.
    HIV Clin Trials; 2015 Sep 10; 16(2):66-71. PubMed ID: 25872972
    [Abstract] [Full Text] [Related]

  • 16. Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.
    Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM.
    AIDS Res Hum Retroviruses; 2019 Sep 10; 35(9):788-793. PubMed ID: 31119944
    [Abstract] [Full Text] [Related]

  • 17. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
    Stranix-Chibanda L, Tierney C, Sebikari D, Aizire J, Dadabhai S, Zanga A, Mukwasi-Kahari C, Vhembo T, Violari A, Theron G, Moodley D, George K, Fan B, Sommer MJ, Browning R, Mofenson LM, Shepherd J, Nelson B, Fowler MG, Siberry GK, PROMISE P1084s study team.
    PLoS One; 2021 Sep 10; 16(2):e0246272. PubMed ID: 33544759
    [Abstract] [Full Text] [Related]

  • 18. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
    Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 and 109 study teams.
    Antivir Ther; 2018 Sep 10; 23(7):623-628. PubMed ID: 30260797
    [Abstract] [Full Text] [Related]

  • 19. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK, Baeten JM.
    Expert Opin Drug Saf; 2016 Sep 10; 15(2):265-73. PubMed ID: 26634852
    [Abstract] [Full Text] [Related]

  • 20. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
    Petruccelli KCS, Baía-da-Silva DC, Val F, Valões MS, Cubas-Vega N, Silva-Neto AV, Sampaio V, Alencar A, Pecoits-Filho R, Moreira RC, Cardoso SW, Moreira RI, Leite IC, Madruga JV, Kallas EG, Alencastro PR, Hoagland B, Grinsztejn B, Santos VGV, Lacerda MVG.
    AIDS Res Ther; 2022 Feb 24; 19(1):12. PubMed ID: 35209929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.